Literature DB >> 26758542

Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Piera Capranzano1, Davide Capodanno2, Chiara Bucciarelli-Ducci3, Giuseppe Gargiulo1, Claudia Tamburino1, Bruno Francaviglia1, Yohei Ohno1, Alessio La Manna1, Salemi Antonella1, Guilherme F Attizzani1, Dominick J Angiolillo4, Corrado Tamburino1.   

Abstract

AIM: Whether high platelet reactivity (HPR) immediately after diagnostic angiography is associated with worse coronary reperfusion prior to and after primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is unknown. This study aimed to assess the impact of P2Y12-mediated HPR on angiographic outcomes in patients with STEMI undergoing PPCI.
METHODS: STEMI patients undergoing PPCI and pretreated with a P2Y12 receptor antagonist underwent platelet function testing with the VerifyNow™ assay at the time of angiography. Light transmission aggregometry (LTA) was performed in a subgroup. HPR was defined according to expert consensus definitions. Pre-PCI coronary patency, thrombotic burden and indices of impaired post-PCI reperfusion were compared between HPR and non-HPR patients.
RESULTS: Among 164 patients, the prevalence of VerifyNow™-derived HPR was 71.3% at a median (interquartile range (IQR)) of 55 (40-75) minutes after a P2Y12 inhibitor loading dose. Compared with non-HPR patients, those with HPR had significantly lower rates of pre-PCI Thrombolysis in Myocardial Infarction (TIMI) flow grades 2 or 3 (51.1% vs. 32.5%, p = 0.04), higher rates of thrombus score (TS) grade 3/4 (29.8% vs. 52.1%, p = 0.015) and 4 (14.9% vs. 32.5%, p = 0.037) and lower median (IQR) corrected TIMI frame count (cTFC; 23.2 (15.8-32.5) vs. 26.0 (21.0-35.0), p = 0.02), respectively. These findings were consistent using LTA-based data. HPR and TS grade 4 were predictors of higher cTFC.
CONCLUSIONS: In patients with STEMI undergoing PPCI pretreated with P2Y12 receptor inhibitors, pre-PPCI HPR was found to be associated with lower pre-PCI coronary patency, higher thrombotic burden and a worse index of post-PCI coronary reperfusion. © The European Society of Cardiology 2016.

Entities:  

Keywords:  Platelet reactivity; ST-elevation myocardial infarction; percutaneous coronary intervention

Mesh:

Substances:

Year:  2016        PMID: 26758542     DOI: 10.1177/2048872615624849

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  3 in total

1.  Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.

Authors:  Mohamed Abo-Aly; Bennet George; Elica Shokri; Lakshman Chelvarajan; Mohamed El-Helw; Susan S Smyth; Ahmed Abdel-Latif; Khaled Ziada
Journal:  J Thromb Thrombolysis       Date:  2020-11-30       Impact factor: 2.300

2.  No-reflow and platelet reactivity in diabetic patients with ST-segment elevation myocardial infarction: is there a link?

Authors:  Wiktor Kuliczkowski; Karol Miszalski-Jamka; Jacek Kaczmarski; Damian Pres; Mariusz Gąsior
Journal:  Postepy Kardiol Interwencyjnej       Date:  2017-11-29       Impact factor: 1.426

3.  Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).

Authors:  Renan Sukmawan; Erick Hoetama; Siska Suridanda Danny; Astuti Giantini; Erlin Listiyaningsih; Vidya Gilang Rejeki; Amir Aziz Alkatiri; Isman Firdaus
Journal:  Pharmacol Res Perspect       Date:  2021-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.